ZOM

Zomedica Corp. (ZOM) | Rumor.io

Zomedica

ZOM

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)31%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about ZOM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0% new	0% +0	0% 0

Jun 30

New alerts have been posted for Zomedica Corp. (ZOM) in the last hours.
Analysts have set a price target for ZOM for next week, but specific details are not provided.
Multiple posts reference ZOM and mention analyst price targets, indicating potential interest in the company's stock performance.

Generated by AI

Sentiment

Of the messages about ZOM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0% 0	0%	0% -100	72.22% +5.45
Bearish	100% 0	100%	100% new	27.78% -5.45

Bullish· Jan 6

Zomedica Corp. (ZOM) is primed for a potential bullish breakout, with a price target analysis suggesting a minimum of $1.20.
The stock has been upgraded by Dawson James, with analyst Jason Kolbert initiating coverage with a Buy rating and a $6 price target.
Zomedica shares are trading higher, with some investors recommending buying and holding the stock for the long term due to the company's strong fundamentals and bright future.

Bearish· Apr 23

$ZOM's market capitalization has fallen below $1 billion, indicating a significant decline in value.
The company's stock price has plummeted from $2.50 to $0.99, suggesting a major downturn in investor confidence.
$ZOM's low market capitalization and declining stock price are indicative of a "cancerous" company with little to no growth potential.

Generated by AI

Topics

Of the messages about ZOM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	48.14%
Announcements	—	—	—	1.98%
Controversies	—	—	—	0%
Earnings	—	—	—	0.16%
Macro	—	—	—	49.72%
Technical Analysis	—	—	—	0%

Announcements· Jan 18

Zomedica Corp. ($ZOM) is taking control of new assay development and manufacturing of the TRUFORMA product line through a long-term licensing agreement with Qorvo Biotechnologies.
This licensing deal is expected to have a positive impact on Zomedica, with shares rising approximately 15% following the announcement.
The company's VetGuardian remote monitoring system has been announced for sale, with a price target of $6 set by Dawson James.

Technical Analysis· Feb 4

$ZOM has shown strength, pushing through resistance on the 4HR chart and is expected to reach $2.
The next resistance for $ZOM is at 1.40, with a potential target of 1.50 if it breaks through.
$ZOM is expected to break through resistance at $1.48, with a possible surge to $1.70 and a target of $1.75.

Generated by AI

Community

Of the messages about ZOM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	8.04%
Newcomers	100%	100%	100%	91.96%

Regulars· Jun 25

The TRUFORMA point-of-care diagnostic platform has secured a CE Mark, expanding Zomedica's market opportunity.
This development is expected to increase the platform's adoption and use in European markets.
The CE Mark certification is a significant milestone for Zomedica's platform, demonstrating its compliance with European health and safety standards.

Newcomers· Jan 18

Newcomers are focused on Zomedica Corp.'s recent licensing agreement with Qorvo Biotechnologies to take control of the TRUFORMA product line, which may have positive implications for the company.
There is a concern among newcomers about CEO Larry Heaton's lack of responsiveness to shareholder inquiries, which they believe may be related to naked short selling.
The stock's recent price drop (-5.72%) and its current trading price ($0.3) are of interest to newcomers, who are also interested in analyst target price predictions for the company.

Generated by AI

July session to spotlight the specialized, coordinated commercial organization that turns product innovation into clinical adoption, sustained utilization, and long-term recurring revenue ANN ARBOR, MI / ACCESS Newswire / July 15, 2026 / Zomedica ...

2mo agoYahoo Finance

Also Discussed

Investors talking about ZOM also mention

#	Name	Attention
1	Castor Maritime Inc.CTRM	0%new
2	Bionano Genomics Inc.BNGO	0%0
3	Check-Cap Ltd.CHEK	0%new
4	Jaguar Health, Inc.JAGX	0.02%-0.02
5	BIOL - BIOLASE, Inc.	——
6	GHSI - Guardion Health Sciences, Inc.	——
7	Tonix Pharmaceuticals Holding CorpTNXP	0.01%+0
8	IZEA Worldwide, Inc.IZEA	0%new
9	Grace Therapeutics Inc.ACST	0%0
10	Inuvo Inc.INUV	0%0

Zomedica Corp.

Location

Social

What share of all stock conversation is about ZOM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0% new	0% +0	0% 0

Jun 30

New alerts have been posted for Zomedica Corp. (ZOM) in the last hours.
Analysts have set a price target for ZOM for next week, but specific details are not provided.
Multiple posts reference ZOM and mention analyst price targets, indicating potential interest in the company's stock performance.

Generated by AI

Sentiment

Of the messages about ZOM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0% 0	0%	0% -100	72.22% +5.45
Bearish	100% 0	100%	100% new	27.78% -5.45

Bullish· Jan 6

Zomedica Corp. (ZOM) is primed for a potential bullish breakout, with a price target analysis suggesting a minimum of $1.20.
The stock has been upgraded by Dawson James, with analyst Jason Kolbert initiating coverage with a Buy rating and a $6 price target.
Zomedica shares are trading higher, with some investors recommending buying and holding the stock for the long term due to the company's strong fundamentals and bright future.

Bearish· Apr 23

$ZOM's market capitalization has fallen below $1 billion, indicating a significant decline in value.
The company's stock price has plummeted from $2.50 to $0.99, suggesting a major downturn in investor confidence.
$ZOM's low market capitalization and declining stock price are indicative of a "cancerous" company with little to no growth potential.

Generated by AI

Topics

Of the messages about ZOM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	48.14%
Announcements	—	—	—	1.98%
Controversies	—	—	—	0%
Earnings	—	—	—	0.16%
Macro	—	—	—	49.72%
Technical Analysis	—	—	—	0%

Announcements· Jan 18

Zomedica Corp. ($ZOM) is taking control of new assay development and manufacturing of the TRUFORMA product line through a long-term licensing agreement with Qorvo Biotechnologies.
This licensing deal is expected to have a positive impact on Zomedica, with shares rising approximately 15% following the announcement.
The company's VetGuardian remote monitoring system has been announced for sale, with a price target of $6 set by Dawson James.

Technical Analysis· Feb 4

$ZOM has shown strength, pushing through resistance on the 4HR chart and is expected to reach $2.
The next resistance for $ZOM is at 1.40, with a potential target of 1.50 if it breaks through.
$ZOM is expected to break through resistance at $1.48, with a possible surge to $1.70 and a target of $1.75.

Generated by AI

Community

Of the messages about ZOM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	8.04%
Newcomers	100%	100%	100%	91.96%

Regulars· Jun 25

The TRUFORMA point-of-care diagnostic platform has secured a CE Mark, expanding Zomedica's market opportunity.
This development is expected to increase the platform's adoption and use in European markets.
The CE Mark certification is a significant milestone for Zomedica's platform, demonstrating its compliance with European health and safety standards.

Newcomers· Jan 18

Newcomers are focused on Zomedica Corp.'s recent licensing agreement with Qorvo Biotechnologies to take control of the TRUFORMA product line, which may have positive implications for the company.
There is a concern among newcomers about CEO Larry Heaton's lack of responsiveness to shareholder inquiries, which they believe may be related to naked short selling.
The stock's recent price drop (-5.72%) and its current trading price ($0.3) are of interest to newcomers, who are also interested in analyst target price predictions for the company.

Generated by AI

Zomedica

Social

Jun 30

Sentiment

Bullish· Jan 6

Bearish· Apr 23

Topics

Announcements· Jan 18

Technical Analysis· Feb 4

Community

Regulars· Jun 25

Newcomers· Jan 18

News

Zomedica Announces "Fourth Friday at Four" Webinar on July 24, 2026: Zomedica's Sales Organization - From Strategy to the Clinic

Also Discussed

Zomedica Corp.

Company Information

Location

Social

Jun 30

Sentiment

Bullish· Jan 6

Bearish· Apr 23

Topics

Announcements· Jan 18

Technical Analysis· Feb 4

Community

Regulars· Jun 25

Newcomers· Jan 18

News

Zomedica Announces "Fourth Friday at Four" Webinar on July 24, 2026: Zomedica's Sales Organization - From Strategy to the Clinic

Also Discussed